Analyst Ratings For RGNX – Regenxbio (NASDAQ:RGNX)
Today, Chardan Capital raised its price target on RGNX – Regenxbio (NASDAQ:RGNX) to $90.00 per share.
Some recent analyst ratings include
- 2/12/2018-Mizuho initiated coverage with a Neutral rating.
- 1/5/2018-Raymond James Financial Reiterated Rating of Buy.
- 11/22/2017-Barclays initiated coverage with a Overweight rating.
- 10/9/2017-Bank of America Reiterated Rating of Buy.
- 8/16/2017-Evercore ISI initiated coverage with a Outperform rating.
Recent Insider Trading Activity For RGNX – Regenxbio (NASDAQ:RGNX)
RGNX – Regenxbio (NASDAQ:RGNX) has insider ownership of 17.00% and institutional ownership of 69.22%.
- On 3/26/2018 Vittal Vasista, CFO, sold 5,000 with an average share price of $30.00 per share and the total transaction amounting to $150,000.00.
- On 3/20/2018 Kenneth T Mills, Insider, sold 10,000 with an average share price of $29.55 per share and the total transaction amounting to $295,500.00.
- On 3/13/2018 Curran Simpson, SVP, sold 25,000 with an average share price of $33.00 per share and the total transaction amounting to $825,000.00.
- On 2/20/2018 Kenneth T Mills, Insider, sold 10,000 with an average share price of $26.56 per share and the total transaction amounting to $265,600.00.
- On 1/22/2018 Kenneth T Mills, Insider, sold 10,000 with an average share price of $27.33 per share and the total transaction amounting to $273,300.00.
- On 1/16/2018 Vittal Vasista, CFO, sold 5,000 with an average share price of $30.16 per share and the total transaction amounting to $150,800.00.
- On 12/22/2017 Curran Simpson, SVP, sold 30,000 with an average share price of $33.03 per share and the total transaction amounting to $990,900.00.
Recent Trading Activity for RGNX – Regenxbio (NASDAQ:RGNX)
Shares of RGNX – Regenxbio closed the previous trading session at 32.92 up +5.72 21.05% with 35.54999923706055 shares trading hands.